Tobira Therapeutics Inc. Highlights Data Presentations At The American Association for Study of Liver Diseases Annual Meeting Supporting Its Phase 2b Program Of Cenicriviroc For Nonalcoholic Steatohepatitis
SAN FRANCISCO, Nov. 8, 2014 /PRNewswire/ -- Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing cenicriviroc (CVC) in liver disease and HIV, announced today that it will be presenting two posters at "The Liver Meeting 2014," an annual international conference organized by the American Association for the Study of Liver Disease (AASLD). Tobira and its research partners will be presenting the results of a recently completed Phase 1 study of CVC in hepatic impaired (cirrhotic) patients as well as an analysis from its completed Phase 2b study in HIV infected subjects showing an improvement in markers of inflammation and liver fibrosis risk scores associated with CVC treatment.
CVC presentations at AASLD:
- Saturday, November 8th Poster Session 1: Fibrosis: Clinical and Translational, 2:00 PM 7:30 PM
Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1 infected adults receiving cenicriviroc over 48 weeks (#455)
M. Thompson; W. Chang; H. Jenkins; A. Flynt; M. D. Gottwald; E. Lefebvre
- Monday, November 10th Late Breaking Poster Session, 8:00 AM 5:30 PM
Pharmacokinetics and safety of multiple-dose cenicriviroc, a novel, oral, once-daily CCR2 and CCR5 antagonist, in adults with mild or moderate hepatic impairment (LB-12)
E. Lefebvre; P. Smith; M. S. Willett; K. C. Lasseter; W. Chang; M. D. Gottwald
About Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, HIV, fibrosis and inflammation. The company's lead product, cenicriviroc (CVC), is a first in class immumodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and HIV. CVC's safety and tolerability profile has been evaluated in approximately 580 subjects who have been dosed in Phase 1 and Phase 2 trials, including 115 HIV-1 infected subjects on treatment for up to 48 weeks. Tobira is currently enrolling patients in CENTAUR, a Phase 2b study of CVC in NASH. Tobira also plans to advance CVC in a fixed-dose combination for HIV type 1 infection through Phase 3 development and commercialization in collaboration with a strategic partner or with non-dilutive financing. Learn more at www.tobiratherapeutics.com. For additional information on the CENTAUR study, please visit clinicaltrials.gov using the identifier NCT02217475.
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking information and forward-looking statements (collectively "forward-looking statements" within the meaning of applicable securities laws). Such statements, based as they are on the current expectations of management of Tobira Therapeutics and upon what management believes to be reasonable assumptions based on information currently available to it, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Tobira's control. Such statements can usually be identified by the use of words such as "may," "would," "believe," "intend," "plan," "anticipate," "estimate" and other similar terminology, or state that certain actions, events or results "may" or "would" be taken, occur or be achieved.
Whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, assumptions and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict. These risks include those inherent in drug development, whether Tobira will be able to obtain financing when needed or on favorable terms, and other risks described in Tobira's filings with the Securities and Exchange Commission. In evaluating any forward-looking statements in this release, Tobira cautions readers not to place undue reliance on any forward-looking statements. Unless otherwise required by applicable securities laws, Tobira does not intend, nor does it undertake any obligation, to update or revise any forward-looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise.
Contacts:
Chris Peetz
Chief Financial Officer
Tobira Therapeutics
(650) 351-5018
cpeetz@tobiratherapeutics.com
Mark Corbae
Canale Communications
(619) 849-5375
mark@canalecomm.com
SOURCE Tobira Therapeutics, Inc.